SGRY Surgery Partners, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Management and operation of surgical facilities primarily focused on outpatient surgical procedures
• • New emphasis: Increased revenue diversification from management and administrative services in non-owned surgical facilities
• • Strategic shift: Improved operational efficiency reflected in decreased general and administrative expenses ratio, from 4.5% in 2024 to 3.6% in 2025
• • Quantitative metric: Revenue growth to $3.31 billion in 2025, up 6.3% from $3.11 billion in 2024, driven by 3.4% volume and 1.4% revenue per case increases
• • Noteworthy fact: Significant increase in interest expense to $272.6 million (8.2% of revenues) due to maturity of interest rate swaps and new unsecured notes

Risk Factors

• • Regulatory risk from One Big Beautiful Bill Act (OBBBA), effective July 4, 2025, increasing Medicaid and Medicare regulatory burdens
• • Macroeconomic exposure to government payors, comprising 42.8% of patient service revenues in 2025
• • Operational risk tied to partnership model with physicians owning majority in 86 of 176 surgical facilities
• • Competitive threat from decline in ophthalmology cases, dropping from 24.4% to 21.7% of surgical mix 2023-2025
• • Financial leverage risk with $692.8 million borrowing capacity under Revolver and $239.9 million cash holdings as of 12/31/2025

Management Discussion & Analysis

• • Adjusted EBITDA $526.2M in 2025 vs $508.2M in 2024, income before taxes $116.9M vs $147.1M in 2024
• • Operating cash flow $274.3M in 2025, Credit Agreement EBITDA $578.2M reflecting acquisitions and synergies
• • Refinanced $1.4B term loans with interest rate ~6.22%, issued $425M senior unsecured notes due 2032 at 101%
• • Net working capital $535.2M at Dec 31, 2025 vs $495.0M in 2024, total debt obligations $5.7B including interest
• • Management highlights economic risks: interest rate inflation could pressure payor mix, patient volume and liquidity; expects capital markets access to meet liquidity needs

What are the latest SGRY SEC filings in 2026?

Surgery Partners, Inc. (SGRY) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on July 24, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did SGRY file its most recent 10-K annual report?

Surgery Partners, Inc. (SGRY) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view SGRY 10-Q quarterly reports?

Surgery Partners, Inc. (SGRY)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every SGRY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has SGRY filed recently?

Surgery Partners, Inc. (SGRY)'s most recent 8-K was filed on July 24, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find SGRY insider trading activity (Form 4)?

SignalX aggregates every SGRY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does SGRY file with the SEC?

Surgery Partners, Inc. (SGRY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SGRY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Surgery Partners, Inc. (SGRY).

What is SGRY's SEC CIK number?

Surgery Partners, Inc. (SGRY)'s SEC CIK (Central Index Key) number is 1638833. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1638833 to look up all SGRY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find SGRY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Surgery Partners, Inc. (SGRY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.